Literature DB >> 28008502

Phosphate metabolism in red blood cells of critically ill neonates.

Gorazd Kalan1, Metka Derganc1, Janez Primožič1.   

Abstract

Very few data exist on phosphate metabolism in critically ill neonates. Therefore we studied the incidence of hypophosphataemia, the intracellular metabolism of phosphate by measuring adenosine 5'-triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG) in red blood cells, and excretion of phosphate in urine. The aims of the study were early detection of changes in phosphate metabolism as possible diagnostic markers of sepsis and defining the cause of hypophosphataemia.Neonates, treated in multidisciplinary paediatric intensive care unit (PICU), included in the study, were less than three days of age. Eighteen of them had respiratory distress syndrome (RDS) and 16 had microbiologically confirmed or clinical sepsis. The overall incidence of hypophosphataemia in critically ill neonates was over 80%, and was more common (88%) and more profound in those with sepsis than in those with RDS (79%). Therefore the septic neonates needed significantly larger amounts of phosphate to maintain normophosphataemia. In septic neonates ATP concentration in red blood cells was significantly lower than in neonates with RDS and controls, while the 2,3-DPG concentration was increased as a result of compensation. In septic neonates urinary losses of inorganic phosphate (Pi) were significantly higher than in neonates with RDS. Hypophosphataemia in critically ill neonates is at least partly due to higher urinary losses of phosphate.

Entities:  

Keywords:  2,3-diphosphoglycerate; Key words phosphate; adenosine triphosphate; neonates; red blood cell

Year:  2000        PMID: 28008502     DOI: 10.1007/s004240000026

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  1 in total

1.  Changes in red cell phosphate metabolism of preterm and fullterm infants with perinatal problems during their first month of life.

Authors:  V Cholevas; A Challa; P D Lapatsanis; S Andronikou
Journal:  Eur J Pediatr       Date:  2007-04-26       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.